A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Lübbe K, Marmé F, Maass N, von Minckwitz G, Grischke EM, Müller V, Schmidt M, Gerber B, Kümmel S, Schumacher C, Krabisch P, Seiler S, Thill M, Nekljudova V, Loibl S.
Bischoff J, et al. Among authors: von minckwitz g.
Anticancer Drugs. 2019 Apr;30(4):394-401. doi: 10.1097/CAD.0000000000000722.
Anticancer Drugs. 2019.
PMID: 30875348
Clinical Trial.